A novel oral agent for HER2-negative advanced or metastatic breast cancer resistant to aromatase inhibitors.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
A novel oral agent for HER2-negative advanced or metastatic breast cancer resistant to aromatase inhibitors.
If you have a Hayes login, click here to view the full report on the Knowledge Center.